Prof. Salman Khan: Leading Researcher in Pharmacology
Summary:
Salman Khan is an accomplished pharmacologist currently serving as an Associate Professor of Pharmacology at Quaid-i-Azam University in Islamabad, Pakistan. Holding a Ph.D., his research focuses on the pharmacological mechanisms of anti-inflammatory, anti-nociceptive, and neuroprotective activities of anomalin and capillarisin under the guidance of Prof. Dr. Yeong Shik Kim.
With a diverse academic and professional background, Salman has held positions such as a Postdoctoral Fellow at McGill University in Canada and Seoul National University in South Korea. His early career includes roles as a Researcher at Kyungpook National University, a Bio-Analyst at Fozan Pharma (Pvt) Ltd. in Peshawar, and various traineeships in organizations like PGMI and Hilton Pharma (Pvt) Ltd.
Salman Khan has been recognized for his contributions with prestigious awards and scholarships, including those from the Canadian Institutes of Health Research (CIHR), BK-21-plus, and the Namgang Award from the Korean Society of Pharmacognosy. His research achievements have earned him accolades such as the Best Research Paper at Seoul National University and multiple Best Poster Awards at international conferences.
Professional Profile:
Education:
- Ph.D. Thesis Title: Pharmacological mechanism underlying anti-inflammatory, anti-nociceptive, and neuroprotective activities of anomalin and capillarisin
- Project Supervisor: Prof. Dr. Yeong Shik Kim
Work Experience:
Organization: Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan
- Designation: Associate Professor of Pharmacology
- Period of Service: March 18, 2021, to present
Organization: Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan
- Designation: Assistant Professor of Pharmacology
- Period of Service: December 01, 2014, to March 17, 2021
Organization: McGill University, Montreal, Canada
- Designation: Post Doc Fellow
- Period: May 01, 2014, to December 30, 2014
Organization: Seoul National University, Seoul, South Korea
- Designation: Post Doc Fellow
- Period: September 01, 2013, to April 30, 2014
Organization: Kyungpook National University, Taegu, Republic of Korea
- Designation: Researcher
- Period: September 2007 to December 2008
Organization: Fozan Pharma (Pvt) Ltd., Peshawar, Pakistan
- Designation: Bio-Analyst
- Period: January 2007 to August 2007
Organization: PGMI, Hayat Abad Medical Complex, Peshawar, Pakistan
- Designation: Trainee
- Period: June 2006 to December 2006
Organization: Hilton Pharma (Pvt) Ltd., Karachi
- Designation: Trainee
- Period: October 2004 to December 2005
Research Funding/International Awards/Scholarships:
Salman Khan has garnered significant recognition and support for his research endeavors through a series of prestigious awards, scholarships, and research funding. His academic journey has been marked by a Postdoctoral award from the Canadian Institutes of Health Research (CIHR) as part of the Neuroinflammation Training Program at McGill University in Montreal, Quebec, Canada. Additionally, he received a Postdoctoral award from BK-21-plus in 2013-2014, granted by the College of Pharmacy at Seoul National University in South Korea.
His achievements extend to international acclaim, including the Namgang Award in 2013 from the Korean Society of Pharmacognosy (KSP) in South Korea. Salman has further demonstrated academic excellence through the receipt of the Graduate Scholarship for Foreign Excellent Students (GSFS) from Seoul National University, spanning the years 2009 to 2013. During his research tenure, he served as a Research Associate with the Korea Food and Drug Administration (KFDA) from 2009 to 2013.
Publication Top Noted:
Title: Physicochemical and mechanical characterization of bacterial cellulose produced with an excellent productivity in static conditions using a simple fed-batch cultivation strategy
- Authors: O Shezad, S Khan, T Khan, JK Park
- Journal: Carbohydrate Polymers
- Volume: 82 (1)
- Pages: 173-180
- Year: 2010
Title: Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-ĪŗB, MAPK and AP-1 via the MyD88 signaling pathway in LPS ā¦
- Authors: J Chun, RJ Choi, S Khan, DS Lee, YC Kim, YJ Nam, DU Lee, YS Kim
- Journal: International immunopharmacology
- Volume: 14 (4)
- Pages: 375-383
- Year: 2012
Title: Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease
- Authors: B Shal, W Ding, H Ali, YS Kim, S Khan
- Journal: Frontiers in pharmacology
- Volume: 9
- Page: 548
- Year: 2018
Title: Suppression of LPSāinduced inflammatory and NFāĪŗB responses by anomalin in RAW 264.7 macrophages
- Authors: S Khan, EM Shin, RJ Choi, YH Jung, J Kim, A Tosun, YS Kim
- Journal: Journal of cellular biochemistry
- Volume: 112 (8)
- Pages: 2179-2188
- Year: 2011
Title: Curcumin therapeutic promises and bioavailability in colorectal cancer
- Authors: A Shehzad, S Khan, O Shehzad, YS Lee
- Journal: Drugs of today
- Volume: 46 (7)
- Page: 523
Research Focus:
Bacterial Cellulose Production:
Research on the physicochemical and mechanical characterization of bacterial cellulose, particularly focusing on its production under static conditions using a fed-batch cultivation strategy.
Anti-Inflammatory Compounds:
Investigation of natural products, such as alantolactone and anomalin, for their anti-inflammatory potential. This involves exploring their effects on inflammatory pathways, including NF-ĪŗB, MAPK, AP-1, and MyD88 signaling.
Neuroinflammation and Alzheimer’s Disease:
Exploration of the anti-neuroinflammatory potential of natural products for the attenuation of Alzheimer’s disease. This suggests a focus on understanding the role of inflammation in neurodegenerative diseases.
Curcumin in Colorectal Cancer:
Examination of curcumin’s therapeutic promises and bioavailability in the context of colorectal cancer. This likely involves studying the anti-cancer properties and efficacy of curcumin in colorectal cancer treatment.